Description
We are seeking a Vaccines Platform Analytical Science and Technology Lead (ASTL) to join our Global Manufacturing Science & Technology department. As Vx Platform ASTL Lead, you will lead a team of Product analytical experts, defining and implementing end-to-end analytical control strategies, supporting technology transfers, and providing technical expertise across the product lifecycle.
Responsibilities:
- Coach and develop a team of Analytical Science & Technology leaders.
- Own end-to-end analytical control strategies, specifications, and comparability process using technical expertise in driving structure-function relationships.
- Lead cross-functional, cross-site teams, covering all analytical aspects in the frame of GSK strategic products and projects.
- Present topics under responsibility and influence global stakeholders within projects governing bodies.
- Coordinate complex analytical investigations, driving problem-solving in creative and practical ways, using advanced data analytics and digital acumen.
- Provide scientific support and mentorship in the development, optimization, and implementation of new methods or modern analytical platform technologies.
- Be accountable for the analytical sections of lifecycle regulatory submissions and RTQ process.
Requirements:
- BSc or higher in a relevant scientific field.
- Senior experience in analytical technologies, method development, and validation.
- Knowledge of Quality by Design, risk management, GMP, NPI, and manufacturing operations.
- Experience supporting regulatory interactions and submissions for vaccines or biotherapeutics.
- Strong leadership and influencing skills in a global matrix environment.
Preferred Qualifications:
- PhD in a relevant scientific discipline.
- Technology transfer, root-cause investigation, and regulatory strategy experience.
- Advanced data analytics, digital fluency, and creative problem-solving.
Benefits:
- Competitive salary: EUR 82,500 to EUR 137,500 (Italy), EUR 118,500 to EUR 197,500 (Belgium).
- Annual bonus and eligibility to participate in share-based long-term incentive program.